However, we divided the patients into a group with high CD8 expression and a group with low CD8 expression, based on CD8 expression levels in the tumor, and performed a meta-analysis for different CD169 expression levels based on CD8 expression. This evidence concerns the gene SIGLEC1 and neoplasm.